Xue et al20 reported that bortezomib inhibited the NF‐κB pathway and induced apoptosis in prostate cancer cell lines; however, prostate cell resistance to BTZ developed after repeated treatment. This evidence concerns the gene NFKB1 and prostate carcinoma.